Btg Pactual Global Asset Management LTD Neurocrine Biosciences Inc Transaction History

Btg Pactual Global Asset Management LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $282,913 - $514,974	-4,141 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $829,603 - $1.06 Million	-8,390 Reduced 66.95%	4,141 $509,000
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $50,149 - $70,589	666 Added 5.61%	12,531 $1.23 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $105,700 - $128,754	1,393 Added 13.3%	11,865 $984,000
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $20,719 - $27,466	354 Added 3.5%	10,472 $813,000
Q3 2017 Nov 14, 2017	SELL	$47.97 - $61.28 $33,770 - $43,141	-704 Reduced 6.51%	10,118 $620,000
Q2 2017 Aug 14, 2017	BUY	N/A	10,822	10,822 $498,000

638

93.8M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Btg Pactual Global Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Btg Pactual Global Asset Management LTD with notifications on news.